Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...
NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
In this retrospective study, researchers stratified pediatric AML patients by risk and aimed to determine whether some could receive fewer chemotherapy cycles without affecting relapse and survival ...
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma To our knowledge, this is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback